Translate Bio, Inc. (TBIO) financial statements (2021 and earlier)

Company profile

Business Address 29 HARTWELL AVENUE
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:654189144
Cash and cash equivalents3428555
Short-term investments31210489
Other undisclosed cash, cash equivalents, and short-term investments(0) (0)
Restricted cash and investments511
Other undisclosed current assets38144
Total current assets:697204150
Noncurrent Assets
Operating lease, right-of-use asset7310
Property, plant and equipment151310
Intangible assets, net (including goodwill)100107128
Goodwill212121
Intangible assets, net (excluding goodwill)7986106
Other noncurrent assets43 
Total noncurrent assets:193133138
TOTAL ASSETS:890336288
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities222312
Accounts payable9165
Accrued liabilities1377
Deferred revenue6818
Debt 1 
Contract with customer, liability3
Other undisclosed current liabilities12  
Total current liabilities:1014214
Noncurrent Liabilities
Long-term debt and lease obligation5112 
Operating lease, liability5112
Liabilities, other than long-term debt381129148
Deferred revenue22925
Contract with customer, liability42
Deferred rent credit  2
Deferred tax liabilities, net0
Business combination, contingent consideration, liability152104104
Total noncurrent liabilities:432141148
Total liabilities:533183162
Stockholders' equity
Stockholders' equity attributable to parent357154125
Common stock000
Additional paid in capital770512371
Accumulated other comprehensive income 10
Accumulated deficit(413)(359)(246)
Total stockholders' equity:357154125
TOTAL LIABILITIES AND EQUITY:890336288

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Gross profit:13981
Operating expenses(194)(124)(106)
Operating loss:(55)(116)(104)
Nonoperating income221
Investment income, nonoperating 21
Other nonoperating income (expense)2(0)(0)
Loss from continuing operations before income taxes:(54)(114)(103)
Income tax benefit 06
Net loss attributable to parent:(54)(113)(97)
Preferred stock dividends and other adjustments  (1)
Net loss available to common stockholders, diluted:(54)(113)(98)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(54)(113)(97)
Comprehensive loss:(54)(113)(97)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1)10
Comprehensive loss, net of tax, attributable to parent:(55)(113)(97)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: